Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN

Xiyao Shi; Xiyao Shi; Ying Wang; Longhui Zhang; Longhui Zhang; Wenjie Zhao; Wenjie Zhao; Xiangpeng Dai; Xiangpeng Dai; Yong-Guang Yang; Yong-Guang Yang; Yong-Guang Yang; Xiaoling Zhang; Xiaoling Zhang

doi:10.3389/fcell.2022.1021820

Frontiers in Cell and Developmental Biology (Sep 2022)

Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN

Xiyao Shi,
Xiyao Shi,
Ying Wang,
Longhui Zhang,
Longhui Zhang,
Wenjie Zhao,
Wenjie Zhao,
Xiangpeng Dai,
Xiangpeng Dai,
Yong-Guang Yang,
Yong-Guang Yang,
Yong-Guang Yang,
Xiaoling Zhang,
Xiaoling Zhang

Affiliations

Xiyao Shi: Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital, Jilin University, Changchun, China
Xiyao Shi: National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital, Jilin University, Changchun, China
Ying Wang: Department of Laboratory Medicine, First Hospital, Jilin University, Changchun, China
Longhui Zhang: Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital, Jilin University, Changchun, China
Longhui Zhang: National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital, Jilin University, Changchun, China
Wenjie Zhao: Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital, Jilin University, Changchun, China
Wenjie Zhao: National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital, Jilin University, Changchun, China
Xiangpeng Dai: Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital, Jilin University, Changchun, China
Xiangpeng Dai: National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital, Jilin University, Changchun, China
Yong-Guang Yang: Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital, Jilin University, Changchun, China
Yong-Guang Yang: National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital, Jilin University, Changchun, China
Yong-Guang Yang: International Center of Future Science, Jilin University, Changchun, China
Xiaoling Zhang: Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital, Jilin University, Changchun, China
Xiaoling Zhang: National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital, Jilin University, Changchun, China

DOI: https://doi.org/10.3389/fcell.2022.1021820
Journal volume & issue: Vol. 10

Abstract

Read online

Bromodomain and extra-terminal domain (BET) family proteins play important roles in regulating the expression of multiple proto-oncogenes by recognizing acetylation of histones and non-histone proteins including transcription factors, which subsequently promote tumor cell proliferation, survival, metastasis and immune escape. Therefore, BET family proteins are considered attractive therapeutic targets in various cancers. Currently, blocking of the BET proteins is a widely used therapeutic strategy for MYCN amplified high-risk neuroblastoma. Here, we summarized and reviewed the recent research progresses for the critical function of BET proteins, as an epigenetic reader, on tumorigenesis and the therapeutic potential of the BET/BRD4 inhibitors on MYCN amplified neuroblastoma. We also discussed the combined therapeutic strategies for BET inhibitor-resistant neuroblastoma.

Published in Frontiers in Cell and Developmental Biology

ISSN: 2296-634X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Science: Biology (General)
Website: https://www.frontiersin.org/journals/cell-and-developmental-biology

About the journal

Abstract

Keywords